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Abstract: Nowadays, cancer is one of the deadliest diseases in the world, which has been estimated
to cause 9.9 million deaths in 2020. Conventional treatments for cancer commonly involve mono-
chemotherapy or a combination of radiotherapy and mono-chemotherapy. However, the negative
side effects of these approaches have been extensively reported and have prompted the search of
new therapeutic drugs. In this context, scientific community started to look for innovative sources of
anticancer compounds in natural sources, including traditional plants. Currently, numerous studies
have evaluated the anticancer properties of natural compounds derived from plants, both in vitro
and in vivo. In pre-clinical stages, some promising compounds could be mentioned, such as the
sulforaphane or different phenolic compounds. On the other hand, some phytochemicals obtained
positive results in clinical stages and were further approved for cancer treatment, such as vinca
alkaloids or the paclitaxel. Nevertheless, these compounds are not exempt of limitations, such as
low solubility, restricted effect on their own, negative side-effects, etc. This review aims to compile
the information about the current phytochemicals used for cancer treatment and also promising
candidates, main action mechanisms and also reported limitations. In this sense, some strategies to
face the limitations have been considered, such as nano-based formulations to improve solubility or
chemical modification to reduce toxicity. In conclusion, although more research is still necessary to
develop more efficient and safe phytochemical drugs, more of these compounds might be used in
future cancer therapies.
Keywords: natural compounds; traditional plants; anticancer; clinical/pre-clinical studies; challenges
1. Introduction
Cancer is one of the deadliest diseases globally and especially in western countries.
According to the International Cancer Observatory, roughly 9.9 million people have died
in 2020 as a result of developing cancer [1]. Cancer is a complex disease, generally defined
as an uncontrolled proliferation and development of cells in tissues forming an amalga-
mation and microenvironment (tumor) that may potentially expand to a whole organ
or systemically to other tissues (metastasis) [2]. This abnormal cell behavior may be the
result of hereditary genetics, or an epigenetic-driven alteration of key genes (oncogenes)
related to the cell cycle and regulation of cell death (apoptosis) [3]. Cancerous cells are also
characterized by dysregulation of programmed apoptosis and aberrant behavior of micro-
tubules, as they are involved in the mitotic process [3]. The World Health Organization
identifies as main causes behind the development of cancer random somatic mutations,
ionizing radiation, reactive oxidative species as well as several chemical and biological
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agents [4]. Except for random mutations, these are widely recognized exogenous carcino-
gens. Ionizing radiation is able to disrupt the hydrogen bonds between nucleic acids as
well as altering their chemical conformation, which may yield alterations in normal DNA
expression regulation [5]. Infectious diseases caused by bacteria, fungi or viruses have
also been significantly correlated with developing cancer afterward in the same affected
tissues. Well-established associations between infections and cancer are viruses like human
papillomavirus to cervix cancer, Herpesvirus to Kaposi’s sarcoma or Hepatitis B and C to
liver cancer. In the same sense, bacterial infections by Helycobacter pylori are linked to gastric
cancer or the genus Salmonella to colon or gallbladder cancer development post-infection [6].
Viruses that integrate their genetic material into the host may alter normal expression of
genes related to cell division or even induce expression of oncogenes that could derive into
oncogenesis. Some examples of these are the integration of Hepatitis B virus into telomeres,
as well as genes coding for proteins X and S, which induce inflammation and neoplasia;
or Human Papilomavirus integration in oncogenes E6 and E7 in the cell genome, which
suppress the p53 anti-tumor gene and promote cell proliferation while simultaneously
alters cell-to-cell adhesion [7–9]. These oncogenes have been related to increased release of
inflammatory mediators like necrosis factor kappaB (Nf-κB) or Activator protein-1 (AP-
1) [8]. Conversely, bacterial infections may elicit the release of toxins with cytotoxic activity
and the disruption of the tissue cell matrix. Known examples are enteric toxins from S. typhi
or CagA and vacuolating toxins of H. pylori, which may induce cell death, neoplasia, and
also alterations in the normal cell metabolism [10,11]. Other infectious pathogens like
fungi and parasitic helminths that produce direct or toxin-mediated tissular damage are
also accounted as oncogenic agents [12]. Aside from specific genetic alterations, the main
recognized tumor-inducing mechanism of biological agents is tissue inflammation as a
result of cell damage and subsequent neoplasia which, if unchecked, can result in potential
chronic inflammation of the affected tissues (e.g., hepatic cirrhosis by Hepatitis virus) [7,13].
Regarding reactive oxygen species, like hydroxide peroxide or hydroxyl radical, which are
normal metabolic products but also arise from contact with oxygen, they are described to
provoke damage and alterations of the cell membranes, lipids or DNA [14]. Indeed, reactive
oxygen species have been identified to increase in tumorous cells, enhancing their prolif-
eration and survivability [15]. Nonetheless, the common factor besides possible genetic
alterations by oxidative stress, infections and ultraviolet radiation is the associated inflam-
matory response [12,14]. On this matter, chronic inflammation is considered both cause
and symptom of other ailments, but particularly of cancer, as tumorous cells secrete several
pro-inflammatory molecules [16]. For example, it is well known that the pro-inflammatory
mediator cyclooxygenase-2 (COX-2) is overexpressed in several types of cancer. As such,
pro-inflammatory mediators are markers of cancer and could be also a possible target
for anticancer therapies [17,18]. Considering chemical carcinogens aside from potential
hazardous substances, the main carcinogens originate in diet. Major chemical carcinogens
include polycyclic aromatic hydrocarbons (PAHs), N-nitroso compounds, heterocyclic
amines (HCAs) and alcohol. PAHs like anthracene appear in combustion reactions, and
are reported in grilled or smoked foods, as well as being part of urban air pollution. They
are linked to lung and digestive tract cancer [19,20]. Closely related in their effects and
occurrence, HCAs like 2-Amino-1-methyl-6-phenylimidazo [4,5-b]pyridine are the result of
pyrolysis of proteins and amino acids in meat or fish foods [21,22]. It is worth mentioning
that tobacco is reported to contain high levels of PAHs and HCAs, linking them to the
pro-carcinogen effects of tobacco consumption [23]. N-nitroso compounds are additives in
processed meats and include nitrites and nitrosamines like N-nitrosedimethylamine that
have been correlated to gastric cancer development [24]. Ethanol as well as other alcohols
present in beverages and spirits induce many metabolic and endocrine disorders along
with being highly cytotoxic chemicals and attributed to cause many types of cancers [25].
Altogether, it should be considered that a variety of exogenous carcinogens from different
sources can heavily prompt cancer development (Figure 1).
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Figure 1. Main causes involved in the development of cancer, according to WHO.
Cancer not only displays heterogeneous cell and tissue-specific behavior, depending
on the onset, inducer and individual genetic profile, but also an unpredictable and diverse
evolution that hinders its treatment [26]. Conventional cancer treatment approach com-
monly involves chemotherapy, radiotherapy and surgery [27,28]. Regarding chemother-
apeutics, their effect is cytostatic, acting through shifting the expression of cell cycle
mediators, disruption of microtubules, or inducers of apoptosis. However, as radiotherapy
and chemotherapy do not discriminate between normal and cancer cells, their application
is paired with certain side effects, ranging from mild gastrointestinal alterations and nausea
to severe gut mucosa dysfunction, cardiovascular toxicity or immunity disorders [29,30].
These side effects, which can linger for long periods after treatment, pose a major issue
when selecting and applying therapeutics.
The ever-growing interest in the search of new therapeutic compounds against cancer
has pushed researchers to look for innovative sources of anticancer compounds in natu-
ral sources, including plants [31]. Traditionally, plants have been used in all cultures for
healing diverse diseases and improve well-being [32,33]. Further research demonstrated
that traditional-used plants contain bioactive compounds, which administered in suffi-
cient doses, have positive effects on health. These effects are attributed to the biological
properties of the compounds, such as antioxidant, anti-inflammatory, antimicrobial and
also anticancer. Nowadays, the potential of plants as sources of anticancer compounds
is both well recorded in traditional medicine and experimental findings [34]. In several
cases, phytochemical compounds have been directly employed or chemically modified
to develop chemicals used in modern medicine, including anticancer drugs. According
with the Food and Drug Administration (FDA), more than the 60% of the drugs employed
in cancer treatment are obtained from natural resources [32]. In Figure 2, a schematic
process for the development of anticancer drugs based on phytochemical compounds is
presented. Briefly, this process starts with the extraction from plants and the testing of
the extracts to evaluate their anticancer potential. Bioactive compounds of the extract are
identified, purified and tested in pre-clinical studies, (both in vitro cell cultures and in vivo
animal models) and later clinical trials in humans [35]. In these studies, some factors such
efficacy, induced tumorigenic changes, possible side effects and toxicity factors must be
deeply characterized [30]. Vinka alkaloids, taxanes, and camptothecin are some examples
of compounds that are currently clinically employed.
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Figure 2. Schematic process for the development of anticancer drugs based on plant-derived compounds.
In general, plant-anticancer compounds have been considered a possible option to
develop new chemotherapeutics and also to enhance the effectivity of the conventional
ones [36–38]. Nevertheless, these compounds present many drawbacks, such as low sta-
bility or solubility, difficulty to be extracted from natural sources and even negative side
effects [39]. Thus, the application of these compounds still has to face several challenges
and further research is necessary. In this review, current information about phytochemical
compounds currently employed clinically in cancer treatment and also promising com-
pounds in pre-clinical and clinical level will be addressed. In addition, the main challenges
lying facing the use of these compounds as therapeutic agents and possible strategies to
solve them will be described.
2. Phytochemicals Currently Used in Cancer Therapy
Along the last decade, many works have compiled ethnomedicinal and ethnophar-
macological uses of very different plant species. Numerous experimental works based on
the evaluation through in vitro and in vivo assays have confirmed the therapeutic appli-
cation of many natural compounds, which have been later included as part of approved
treatments, including in anticancer agents (Figure 3) [40].
This section summarizes current available information regarding the clinical status
of the main plant compounds proposed for cancer treatment. Vinka alkaloids, taxanes,
camptothecin derivatives, podophyllotoxin and derivatives and roscovitine are the most
used in clinical studies. Table 1 collects an overview of the data supporting the development
of plant compounds as anticancer agents, including clinical trials and clinical uses.
2.1. Vinca Alkaloids
The vinca alkaloids is a large group of about 130 terpenoid indole alkaloids, naturally
found in Catharanthus roseus leaves [31]. These compounds were one of the first plant
alkaloids used in the development of anticancer drugs. Currently, several vinca alkaloids
are in clinical use for cancer treatment: vinblastine, vincristine and also semi-synthetic
derivatives, such as vinorelbine, vindesine, or vinflunine [45–47]. These compounds are
considered small tubulin-binding molecules. The interaction with the tubulin proteins in
the mitotic spindle avoids its polymerization into microtubules, inhibiting the cell mitosis.
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Thus, the cells remain in a prolonged arrest phase and finally die [48]. Vincristine has
been demonstrated to possess highest affinity for tubulin than vinblastine, and even than
the vinca derivatives vindesine and vinorelbine [47,49,50]. The dimeric nature of these
alkaloids has been described to act through two ways. Vindoline moiety has been proposed
to bind the β-subunit of tubulin heterodimers, which ultimately inhibits mitosis and leads
to apoptosis. Catharanthine moiety has less potent effect on α/β-tubulin polymerization.
However, different genes have been demonstrated to be sensitive to this molecule, such
as those related with cell-to-cell signaling and interaction, which may be related with its
capacity to induce cytotoxic effects [51].
Figure 3. Main mechanisms of phytochemical compounds employed in cancer therapy.
In the 60s, Food and Drug Administration (FDA) approved the clinical application of
vinblastine and vincristine, becoming very incipient plant-derived anticancer agents [40],
usually combined with other compounds [52]. Vinblastine has been used in for the treat-
ment of Hodgkin’s disease, apart from testicular carcinoma, breast cancer and germ cell
tumors [53,54]. In a small phase II study of thalidomide and vinblastine in chemotherapy-
refractory Hodgkin’s Lymphoma, both drugs demonstrated encouraging activity with
some durable responses and acceptable toxicity [55]. In another phase II study carried
out from 2001 to 2003 with patients posing advanced solid tumors, it was observed that
the combination of daily cyclophosphamide and weekly vinblastine, administered con-
currently with daily rofecoxib, provided moderate anticancer activity [56]. Moreover, the
use of neoadjuvant chemotherapy with cisplatin, methotrexate, and vinblastine in patients
with muscle-invasive urothelial bladder cancer treated by cystectomy and/or radiotherapy
has been internationally investigated with 966 patients in the early 1990s [57]. The results
showed that chemotherapy with cisplatin, methotrexate, and vinblastine improves outcome
as first-line adjunctive treatment for invasive bladder cancer. Vinblastine was approved
in Europe in 2009 for second-line treatment of metastatic and advanced urothelial cancer
after failure of therapy with platin. Since then, the medicine was used in some clinical
trials with successful results [58]. Vincristine has been used in chemotherapy in adults and
children for treating acute leukemia but it has been also applied to treat rhabdomyosar-
coma, neuroblastoma, Wilm’s tumor, Hodgkin’s disease and other lymphomas. Besides,
it represents a treatment for non-malignant hematologic disorders like autoimmune and
thrombotic thrombocytopenia, and hemolytic uremic syndrome.
2.2. Paclitaxel
In this group of molecules, the most recognized compound is paclitaxel, one of the
most effective and promising therapeutic drugs available against a wide range of cancers.
This compound has been identified in different species of the genus Taxus such as Taxus
brevifolia, T. baccata, T. media or T. cuspidate [59]. It is an anti-neoplastic agent which acts
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as a microtubule’s stabilizer and mitosis inhibitor. Its main antitumor effect is derived
from the compound binding the β-sub-unit of tubulin, which inhibits the microtubule
depolymerization into tubulin and stops the cell cycle in the G2/M phase, leading to cell
death [60].
Table 1. Anticancer compounds employed in clinical treatment of cancer [41–44].
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FDA first approved Taxol® for the treatment of ovarian cancer in 1992. Nowadays, the
human prescription indications and uses of this drug comprise Kaposi’s Sarcoma, breast
cancer, ovarian cancer, microcytic lung malignant neoplasm. In addition, it is often used
to treat several cancers including oesophageal, bladder, prostate, cervical, gastric, head,
neck and testicular cancers [61]. Nevertheless, paclitaxel has few drawbacks, such as low
hydrosolubility, present side-effect and patients can develop resistance to the drug. Among
them, the development of multidrug resistance that has limited its therapeutic efficacy has
been not totally explained, although few potential mechanisms have been suggested, like
α-/β-tubulin mutations and/or alterations in the binding regions [54].
2.3. Camptothecin and Irinotecan
Camptothecin is a natural compound with potent antitumor activity, isolated in 1966
from the bark of Camptothecin acuminata. This molecule binds to the TOP1 cleavage
complex, leading to an accumulation of DNA strand breaks during replication, causing
apoptosis in the S phase of the cell cycle [62]. The use of camptothecin in clinical applica-
tions has shown some limitations derived from its poor solubility and stability [63]. For
this reason, several stable derivatives are currently under study in clinical trials, from
which only two can be used in clinical studies by the US Federal Drug Administration.
One of them is irinotecan, approved in 1996 as a therapy agent for refractory colorectal
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carcinoma [64]. This compound is now widely used to treat other types of cancer, includ-
ing lung, although the dose limiting toxicity of this antitumor agent includes diarrhea,
neutropenia and severe leukopenia [65]. The second compound is Topotecan, approved
in 2007 as a secondary agent for therapy of ovarian cancer or small cell lung cancer [66].
However, some studies have revealed that therapeutic use of irinotecan is limited due to
its hydrophobicity, low stability at physiologic pH, and side effects.
2.4. Podophyllotoxin and Analogues
Podophyllotoxin is an important plant-derived natural product isolated from Podophyl-
lum peltatum and Podophyllum emodi [35]. It has a lignan as interesting molecule, which
can be semisynthesized commercially, showing antitumor activity against different types
of cancers, such as cervical carcinoma, osteosarcoma, nasopharyngeal carcinoma, colon
cancer, breast cancer, prostate cancer, small cell lung cancer and testicular carcinoma [67].
The mechanism of action of podophyllotoxin is related to the blockage of cell division
in the metaphase of mitosis due to the inhibition of microtubule assembly in the mitotic
apparatus [35]. However, their derivatives etoposide and teniposide are not inhibitors of
microtubule assembly, but act via interaction with DNA and inhibition of DNA topoiso-
merase II [35].
The initially clinical use of podophyllotoxin was declined rapidly, due to its unaccept-
able side effects, including nausea, vomiting, and damage to normal tissues [68]. However,
due to its remarkable inhibitory effect on tumor cell growth and extensive use in traditional
medicine, podophyllotoxin has constituted an important starting point in the development
of three of the most highly prescribed anticancer agents worldwide: etoposide, teniposide,
and the water-soluble prodrug etoposide phosphate [68]. The podophyllotoxin derivatives
are gaining attention for clinically trials having wider use of podophyllotoxin scaffolds in
medicine. In a randomized clinical trial, the effects of podophyllotoxin on anogenital warts
with imiquimod 5% cream were compared. The study led to the conclusion of a strong
inhibitory effect on warts growth in patients treated with podophyllotoxin versus patients
treated with imiquimod cream [69].
2.5. Roscovitine
The agent Roscovitine (generic name Seliciclib) is a purine-based anticancer com-
pound, isolated from the cotyledons of Raphanus sativus L. (Brassicaceae) [31]. This com-
pound is a potent inhibitor of cyclin-dependent kinases (CDK) CDK1, CDK2, CDK5, CDK7,
CDK9 and CDK12, through direct competition at the ATP-binding site [70,71]. As an
inhibitor of the CDK family, roscovitine has an important impact upon several funda-
mental processes in cells [72]. CDK1 and 2 are involved in the control of the initiation
and progression of cellular division. Then, the inhibition of these kinases leads to the
reduction of the cell proliferation. The inhibition of CDK7, CDK9 and CDK12 results in
downregulation of a large number of genes [71]. This compound has been tested in several
phase I and II clinical trials showing its anticancer activity. Roscovitine was used in phase I
clinical trial against glomerulonephritis, in phase II clinical testing against lung and breast
cancer and currently, it is in a phase II clinical trial in patients with Cushing disease [73].
Roscovitine has also been tested in a phase I trial in combination with gemcitabine and
cisplatin in non-small cell lung cancer patients and the results revealed that the 70% of the
patients with nasopharyngeal tumors showed stable disease during the study [72]. Another
example supporting the anticancer activity of this molecule is a phase I trial study in which
roscovitine was orally administrated to patients with refractory solid tumors. In this case,
although no tumor reductions were observed, roscovitine induced a stable disease in some
patients [72]. Other studies in vivo revealed that roscovitine causes significant selective
DNA damage in head and neck cancer cells and in human papilloma virus-positive (but not
in human papilloma virus-negative) [74]. These results support the potential of roscovitine
as a drug against human papilloma virus and head and neck squamous cell carcinoma.
However, a phase II trial performed with almost 200 patients suffering with non-small cell
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lung cancer has failed. The study has met the primary endpoint of improving progression
free survival, although patients administered with roscovitine did show longer median
survival [72].
3. Compounds in Pre-Clinical and Clinical Stages
Numerous phytochemical compounds have demonstrated to exert significant anti-
cancer activity in pre-clinical studies (both in vitro and in vivo). These positive results
led to their evaluation in further clinical trials, to estimate the suitability (preliminary
efficacy, toxicity, pharmacokinetics, safety data, etc.) of the compounds as possible agents
in new strategies for cancer therapy (several examples have been compiled in Table 2). In
this section, some of these compounds will be described, including colchicine derivatives,
sulphoraphane and dietary phenolic compounds, such as resveratrol, curcumin, quercetin,
gingerol and kaempferol. Nowadays, several pre-clinical and clinical studies have been
conducted with these compounds, but more clinical trials are still necessary before their
further application.
Table 2. Examples of clinical trials carried out with the selected phytochemical compounds.
Compound Type of Cancer Main Results Refs.
Sulforaphane
Prostate
Reduction of prostate-specific antigen after
prostatectomy/Lengthening of the on-treatment
prostate-specific antigen doubling time.
[75,76]
Breast Improved efficacy of doxorubicin, without any cytotoxic effect. [77]
Resveratrol
Colorectal Induction of apoptosis in malignant cells in hepatic metastasis. [78]
Breast Reduction of DNA methylation of RASSF-1α and prostaglandinE2 expression. [79]
Prostate Reduction of cancer recurrence. [80,81]
Curcumin
Pancreas Improved efficacy of gemcitabine, without any cytotoxic effect. [82]
Breast Improved efficacy of paclitaxel, without any cytotoxic effect. [83]
Quercetin Gastric High dietary intake is inversely related to the risk of cancerdevelopment. [84]
Gingerol
Colorectal Reduction of the risk of cancer development. [85]
Solid tumor
Enhanced antioxidant status of patients receiving
chemotherapy/Improvement of general quality of cancer
patients receiving chemotherapy.
[86,87]
Kaempferol Ovarian Reduction of the risk of cancer development. [88,89]Pancreatic
3.1. Colchicine Derivates
Colchicine is a natural alkaloid that was initially isolated from plants that belong to
the genus Colchicum such as Colchicum autumnale. Later, its presence was also confirmed in
other vegetal species like those from genera Gloriosa and Sandersonia. This compound is
considered a tubulin poison because it suppresses microtubule dynamics, which ultimately
disrupts the formation of the mitotic spindle. Colchicine, through its specific colchicine
domain-binding, gets bound to tubulin between both α and β subunits which subsequently
stimulates the depolymerization of tubulin complexes. This destabilization of microtubules
is capable of arresting cell cycle at different phases leading to a final induction of the cell
apoptosis [90]. Colchicine was initially evaluated as cancer therapy, but it presents few
drawbacks: it possesses high toxicity and shows low specificity for tumor cells that lead
it to target normal cells. Hence, colchicine has a limited medical application in cancer
therapy. Nevertheless, semisynthetic derivatives that present lower toxicity have been
developed and successfully applied on in vitro studies. Colchicinamide, deacetylcolchicine
or valyl colchicine and other synthetic derivatives have been tested in different in vitro
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human cancer cell lines such as colorectal, chronic granulocytic leukemia, melanoma,
central nervous system and breast cancers [36,91–93]. It seems that deacetylcolchicine has
been employed in clinical trials, due to its effectiveness against melanoma, Hodgkin’s
lymphoma, and chronic granulocytic leukemia [94], but, to our knowledge, no other
clinical trials with colchicine derivatives have been reported. Most of the studies evaluating
colchicine derivatives have been carried out in vitro. Some of these compounds have been
considered more active and selective, compared to colchicine [92,93], but more pre-clinical
and clinical trials are still necessary to assess the efficacy, pharmacokinetics, limitations
and safety issues of these compounds, before considering them possible candidates for
future cancer treatment.
3.2. Sulforaphane
Sulforaphane (1-isothiocyanate-4-methyl-sulfinylbutane) (SFN) is the best-known
compound of the isothiocyanate group [95]. It is a redox-active natural molecule isolated
for the first time in 1958 from the leaves of hoary cress (Lepidium draba). Afterwards,
in 1992, it was found in plants from the Brassicaceae family. Today, this compound is
well known to be found in foods and specifically in cruciferous vegetables like broccoli
sprouts [96]. In fact, some studies show that extracts from broccoli can induce the phase
II detoxification enzymes and the antioxidant enzymes in mammalian cells [97]. SFN
has been tested for cancer prevention, cancer therapy and also in other chronic disease
prevention and treatment bioassays [98]. This compound has regulatory effects on the
tumor cell cycle, apoptosis, and angiogenesis by modulation of the related signaling
pathways and genes [99]. In the analysis of the cell cycle, it was observed that SFN causes
G2/M phase arrest, leading to inhibition of tumor proliferation/growth, which is associated
with downregulation of cyclin B1 and cyclin D1 genes (related with the progression of the
cell cycle), as well as increased protein levels of cyclin/CDK inhibitor p21 (related with
cellular senescence). SFN also increased the expression of the pro-apoptotic protein Bax
and decreased expression of the anti-apoptotic protein Bcl-x, inducing apoptosis in cancer
cells [99].
In the last years, the anticancer properties of this compound have been demonstrated
in vitro and in vivo, and a few clinical trials have been carried out tenting the suitability of
oral-supplementation of SFN for cancer chemoprevention and also in combination with
other anticancer drugs [100,101]. Clinical trials have been performed on prostate and
breast cancer patients. In a double-blinded, randomized, placebo-controlled trial, the
oral administration of SFN lead to the significant reduction of prostate-specific antigen
in prostate cancer patients after radical prostatectomy [75]. In a phase II clinical trial on
prostate cancer patients with biochemical recurrence after prostatectomy, patients who
received oral administration of SFN showed a lengthening of the on-treatment prostate-
specific antigen doubling time, compared to pre-treatment [76]. In a recent phase II clinical
trial, the results showed that the administration of SFN as adjuvant enhanced the efficacy
of doxorubicin against in vivo breast cancer [77]. More studies about clinical uses of
SFN in humans seems warranted, due to the high availability and tolerability of this
compound, and its effectiveness as a chemoprevention agent in preclinical models of
carcinogen-induced cancer [102].
3.3. Phenolic Compounds
Some of the most promising compounds that may be in the development of new
drugs are phenolic compounds. These compounds are secondary metabolites from plants
(an also some algae), which could be divided into phenolic acids, flavonoids, lignans,
stilbenes and other compounds [103]. Nowadays, these compounds have attracted the
attention of scientific community due to their large range of biological properties, such as
antioxidant, anti-inflammatory, antibacterial and also anticancer [104–107]. Due to their
beneficial effects on health, the interest of the consumption of phenolic compounds has
increased [108]. Regarding anticancer activity, it has been described that these compounds
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may interfere with the initiation, growth and progression of cancer by modulating different
enzymes and also diverse signaling pathways related with cell-proliferation [105]. Several
examples of phenolic compounds employed in pre-clinical and clinical studies have been
described below.
3.3.1. Resveratrol
Resveratrol is a phenolic compound present in some fruits, such as grapes, peanuts,
blueberries and blackberries. Numerous studies have evaluated the anticancer proper-
ties of this compound. Several action mechanisms of resveratrol have been described:
positive regulation of p53 and BAX proteins (related with pro-apoptotic pathways) and
negative regulation of NF-κB, AP-1, hypoxia-inducible factor 1-alpha (HIF-1α), matrix
metalloproteases, Bcl-2 protein, COX-2, cytokines and CDK [109]. Some pre-clinical studies
performed in vitro demonstrated that resveratrol was able to suppress the cell proliferation
through cell cycle arrest, induce apoptosis and modulate autophagy in different cancer
cell lines, including ovarian cancer cell line, resistant human leukemia cells, non-small-cell
lung cancer and human lung adenocarcinoma [110–112]. Regarding in vivo studies, the
anticancer properties of this compounds were also significant. For example, in an in vivo
study, resveratrol was administered to mice, leading to a 60% reduction in the appearance
of sporadic colorectal cancer. Similarly, resveratrol inhibited cell proliferation, induced
the apoptosis and suppressed the angiogenesis and metastasis in bladder cancer mice-
models [113]. Resveratrol has been also reported to enhance the efficacy of traditional
chemotherapeutic drugs, including temozolomide, doxorubicin and paclitaxel in mice
models [114–116].
The positive results obtained at pre-clinical level led to the development of clinical
studies using this compound. For example, in 2011, a phase I study conducted with
colorectal cancer patients with hepatic metastasis reported that the administration of
microparticular-formulated resveratrol (5 g/day, 14 days) increased the apoptosis of malig-
nant cells in the hepatic tissue, compared with placebo [78]. In colorectal adenocarcinoma,
resveratrol reduced the expression of COX-2 and M1G (NCT00433576). In another study, the
results showed that trans-resveratrol (100 mg/day, 12 weeks) reduced the DNA methyla-
tion of RASSF-1α, a gene related with breast-cancer, and also reduced the cancer promoting
prostaglandin E2 expression in the breast [79]. A phase I study conducted with recurrent
prostate cancer patients with elevated prostate-specific antigen levels evaluated the effects
of the administration of pulverized muscadine grape skin extract containing resveratrol
(4000 mg). The results showed a significant reduction of the recurrence of the cancer by
more than 5 months, compared with placebo [80]. A further 12-month study reported simi-
lar results using two different doses, 500 and 4000 mg of resveratrol [81]. Regarding these
clinical trials, the use of resveratrol may be promising in cancer treatment. However, one of
the main drawbacks of resveratrol is its low water-solubility, which limits its clinical use. To
overcome this limitation, some strategies have been considered such as synthesis of novel
derivatives and analogues [116], micro-formulation [78] or nano-delivery systems [117].
3.3.2. Curcumin
Curcumin is a natural pigment of phenolic nature extracted from Curcuma longa.
This compound has been extensively studied due to their immunomodulatory and an-
ticancer properties, among others [118]. Numerous biological targets of curcumin have
been described, such as proteins involved in the antioxidant-response, apoptosis, cell-cycle
regulation and cancer progression [119]. Numerous pre-clinical studies have demonstrated
that curcumin is an effective chemopreventive agent and also acts as a beneficial adju-
vant [120]. To cite some examples, in vitro assays reported that curcumin exerted anticancer
effects (reduction of cell proliferation, cell cycle arrest, apoptosis, autophagy, etc.) in differ-
ent cells lines, such as human endometrial, malignant glioma, malignant mesothelioma,
breast adenocarcinoma, melanoma, chronic myelogenous leukemia or gastric cancer cell
lines [116,121–124]. In vivo studies have reported similar results, for example, in chronic
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myeloid leukemia [123], pancreatic cancer [125] or breast cancer mice models [126]. Cur-
cumin has been also reported to enhance the effects of conventional drugs, such as cisplatin,
doxorubicin, paclitaxel or irinotecan [127,128]. Nevertheless, this compound present low
bio-availability, due to its low solubility, which limits its clinic applications. In this sense,
nanoparticles-based drugs or derivative compounds have been reported to be suitable
options to developed curcumin treatments [119,126].
Despite bioavailability limitations, to date, several clinical studies have evaluated
the potential of curcumin against different cancers: breast, prostate, pancreatic, colorec-
tal and hematological [35,116]. More recently, a study assessed the efficacy of curcumin
complexed with phospholipids as complementary treatment of gemcitabine on pancreatic
cancer patients. The results showed that the administration of the product (2000 mg/day)
increased the efficacy of gemcitabine, without any observed toxicity [82]. Similar effects
were observed in a II phase study, where curcumin was tested as complementary treat-
ment of paclitaxel in metastatic and advanced breast cancer. The treatment with both
compounds was more efficient compared with paclitaxel-placebo and no toxic effects were
observed [83]. As a function of these results, it seems guaranteed that curcumin could be
used in combination with the conventional drugs to enhance their efficacy in the future.
3.3.3. Quercetin
Quercetin is a flavonoid commonly found in berries, onions and leafy vegetables, to
which anticancer properties are attributed [129]. In this sense, numerous studies in vitro
and in vivo pre-clinical studies have showed positive results. Regarding its action mecha-
nisms, quercetin has been demonstrated to induce cell cycle arrest by regulating cyclin D1
and p53-related pathways; apoptosis trough the induction of pro-apoptotic factors and the
decrease of anti-apoptotic ones; induces autophagy and inhibits proliferation, angiogenesis
and metastasis [130,131]. These effects have been observed in different in vitro cell lines,
including breast, ovarian, lung and colon cancer cells, among many others [130,132,133],
and also in different in vivo mice models [134–136]. Furthermore, quercetin has been
reported to enhance the efficacy of chemotherapeutic drugs [137,138].
Regarding clinical trials, several have evaluated the suitability of quercetin as anti-
cancer drug. For example, a study conducted on humans reported that a high intake of
quercetin in the diet is inversely related to the risk of gastric adenocarcinoma [84]. An-
other study evaluated the use of quercetin to prevent and treat oral mucositis induced by
chemotherapy. The results showed a significant reduction of oral mucositis incidence in the
quercetin treated group, which may suggest that this compound could be used to palliate
chemotherapy side-effects [139]. Nowadays, some clinical trials are ongoing in prostate
(NCT01912820), squamous cell carcinoma (NCT03476330) and lung cancer (NCT04267874).
However, in some cases, the results are limited due to the low solubility and bioavailability
of this compound. To overcome these drawbacks, several delivery systems have been
proposed for instance, lipids, nanoparticles, nanoemulsions, liposomes or micelles [131].
3.3.4. Gingerol
Gingerol is another phenolic compound with significant anticancer properties, ex-
tracted from the fresh rhizome of Zingiber officinale. The action mechanisms attributed
to gingerol include reduction of inflammation (decrease of NFκB and COX-2), induction
of phase II detoxification enzymes (Nrf2), genomic instability (tubulin interactions), and
altered gene expression (increased expression of pro-apoptotic molecules and decreased
expression of anti-apoptotic factors), among others [140]. These effects have been cor-
roborated in different in vitro cultures, such as neuroblastoma, sarcoma, human myeloid
leukemia, breast Caco-2 cancer cells, and also in breast cancer-animal models [141–145].
Recently, studies have demonstrated that gingerol may be used in combination with cis-
platin [146] or doxorubicin [145], to improve their efficacy.
Several clinical trials have employed ginger root extracts, containing gingerol, to
determinate its ability to prevent cancer development. In a pilot study, patients at increased
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risk for colorectal cancer received 2 g of ginger (standardized to 5% of gingerol). The
results suggested that ginger supplementation might be effective to prevent the apparition
of cancer [85]. In other pilot study, newly diagnosed cancer patients received a ginger
extract (standardized 6-gingerol 20 mg/day) as chemotherapeutic adjuvant, starting 3 days
prior to the first cycle of chemotherapy till the fourth cycle. The results obtained showed
that the antioxidant status was increased and oxidative markers were reduced in the
ginger group, suggesting that daily supplementation could reduce the negative effects of
chemotherapy [86]. Recently, a phase II, randomized, double-blind, placebo-controlled
study confirmed that 6-gingerol significantly improved the overall complete response rate
in chemotherapy-induced nausea and vomiting, appetite, and quality of life in cancer
patients receiving chemotherapy [87]. It has been described that gingerol has low solubility
in water, leading to low bioavailability and limited applications. Several strategies may
be employed to overcome these drawbacks, such as proliposomes [147], nanostructured
lipid carriers [148] or microemulsion [149], achieving higher bioavailability and activity,
compared to free gingerol.
3.3.5. Kaempferol
Kaempferol is one of the most common flavonoids, found in diverse fruits and vegeta-
bles. Many studies have described the beneficial effects of dietary kaempferol in reducing
the risk of chronic diseases, especially cancer [150]. Kaempferol increases the body’s antiox-
idant defense against free radicals, which have been demonstrated to be one of the main
causes involved in cancer development. At molecular level, kaempferol has been reported
to modulate several key elements in cellular signal transduction pathways linked to apop-
tosis, cell-cycle arrest, angiogenesis, inflammation and metastasis [150,151]. Nowadays,
several pre-clinical in vitro and in vivo studies have reported the anticancer properties of
this flavonoid against different types of cancers, including breast, prostate, ovarian, lung,
colon or kidney [152].
Several clinical studies have evaluated the relation between the intake of dietary
flavonoids (including kaempferol) and cancer, showing variable results. Many studies
have reported no significant relation between oral intake of kaempferol and risk of cancer
development [153], ovarian [154] or breast cancer [155]. On the other hand, some clinical
studies have reported significant reduction in ovarian cancer [88] and the risk of pancreatic
cancer development in smokers [89]. Considering these results, it would be necessary
to perform more clinical studies with larger groups. In addition, like other phenolic
compounds, the clinical applications of this compound are limited by its poor bioavailability.
In this sense, nano-formulations, phospholipids or metallic complex could be strategies to
enhance the bioavailability of these compounds and thus, their bioactivity [152,156].
3.4. Other Plant Derived Compounds
Other plant-derived compounds that have demonstrated anticancer properties both
on in vitro and in vivo studies have been compiled in Table 3. The results obtained in
pre-clinical stage could led to the development of more clinical studies and the design of
new chemotherapeutics.
Table 3. Anticancer compounds obtained from plants.
Plant Compound Structure Results (IC50 µM) Refs.
Aloe vera Emodin
In vitro: Breast (8.6); Lung (19.6); Liver (12.8)
Induction of apoptosis, specific
energy-dependent pathway of drug
incorporation.
[157,158]
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Table 3. Cont.




In vitro: Lung (0.9)
Production of reactive oxygen species, inhibition
of cell cycle in G0/G1 phase, induction of
apoptosis, inhibition of angiogenesis.
[159]
Artesunate
In vitro: Breast (2.3); colon (1.9); lung (9.8);
leukemia (2); ovarian (15.0)





In vitro: Human leukemia (2.6); murine leukemia
(2.1); cervix (2.5); colon (10.0); lung (4.3); skin
(8.0); gastric (13.0) In vivo: (mice): Breast (13.5)
Activation of extrinsic apoptosis pathway via up
regulation of DR4, DR5 and PARP cleavage.
[163–166]
Betulin
In vitro: Breast (30.7); colon (45.2); lung (45.2);
leukemia (14.5); skin (6.8); prostate (17.9)




In vitro: Breast (25)/In vivo: Breast (25.0); colon
(25.0)
Induction of cell cycle arrest, synergistic effect
with drugs/Reduction of tumor volume and






In vitro: Breast (350.0); colon (1000); lung (78.0)
Induce apoptosis of cancer cell lines. [170]
Epicatechin In vitro: Colon (60); prostate (8.9); ovarian (7.9)Growth inhibition. [171]
Epigallocatechin In vitro: Breast (22.0); colon (75.0); lung (70.0)Growth inhibition. [172]
Combretum
caffrum Combretastatin
In vivo (mice): Breast (80-190); colon (8.4;) lung
(7.1); leukemia (1.9)
β-tubulin binding, causing the destabilization of
the microtubules.
[161,173]
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Plant Compound Structure Results (IC50 µM) Refs.
Crocus sativus
Crocetin
In vitro: Colon (0.2); lung (0.4); liver (0.6)




Inhibition of cancer cells’ proliferation or/and




In vitro: Colon (20.0)
Apoptosis and G2/M cell cycle arrest mediated






In vitro: Breast (23.9); colon (22.2); lung (15.2);






In vitro: Lung (351.5); medullobalstome (293.5)
Activation of mitochondrial execution pathway
by Caspase-9 and -3; increase levels of Bax in




Inhibitor of mitochondrial uncoupling protein 2,
induction caspase-dependent apoptosis in vitro




In vivo (mouse): Breast 10.0; colon 5.0; lung 10.0;
prostate 5.0
p62/SQSTM1-mediated autolysosome formation
and redox setting; inhibition of signal transducer
and activator of transcription 3 activity.
[182–184]
Bilobetin In vitro: Breast 57.6; lung 36.4; leukemia 46.0Arresting the G2/M phase of the cell cycle. [185]
Isoginkgetin In vitro: Breast 91.2; lung 43.0; skin 18.8Arresting the G2/M phase of the cell cycle. [185]
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Table 3. Cont.




In vitro: Lung (30.0); skin (50.0); liver (44.13);
gastric (42)
Increased mRNA expression of DR3, DR5,
caspases-3, caspases-8, caspases-10, Fas, Bad, Bax,




In vitro: Breast (28.6;) colon (25.4); leukemia
(12.2); kidney (35.21)




Apigenin In vitro: Breast (100;) lung (93.7); liver (38.9)Up-regulation of DR5 pathway. [189]
Chamomillol
In vitro: Breast (300.0); colon (165.0); prostate
(200.0); liver (300.0)





In vitro: Colon (25.0); liver (1.2)
Regulation of cell cycle transition and the
induction of apoptotic cells.
[192]
Ginsenoside
In vitro: Breast (30.0); colon (100.0); lung (50.0);
skin (25–100)




In vivo (mice): Breast (45.0); lung (73.0); leukemia
(20.0); pancreas (70.0)





In vitro: Breast (20.5)
Inhibition of proliferation. [195]
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Plant Compound Structure Results (IC50 µM) Refs.
Salvia prionitis
Salvicine
In vitro: Breast (1.4); leukemia (3.6); stomach (1.8)




In vivo (mice): Breast (1.1;) lung (20.0); leukemia
(4.8)
Multispecific modes of actions: G2/M arrest,
apoptosis, inhibition of cellular movement.











In vitro: Breast (24.0); skin (100.0); prostate (55.6);
ovarian (25.0)
Induction of apoptosis and cell cycle arrest.
[203–205]
Silymarin
In vitro: Breast (75); prostate (67.9)
Interference with expressions of cell cycle
regulators and proteins involved in apoptosis;





In vitro: Breast (20.4;) colon (10.4); leukemia (100);
liver (>100).
Reduction of cell viability.
[208,209]
Shogaol




4. Current Challenges of Anticancer Phytochemicals
The development of phytochemical anticancer agents requires substantial evidence
of efficacy derived from adequate clinical trials before their approval for use in patients.
Although the mentioned compounds present significant anticancer properties, they also
have limitations that should be overcome before its further clinical application, in the case
of compounds in clinical stage, or to enhance their characteristics, in the case of drugs
currently used in cancer treatment. In this sense, poor aqueous solubility, poor penetration
to enter in targeted cells, absorption by normal cells, limited therapeutic potential and
toxic side effects are still the major concern of the application of phytochemical compounds
in cancer treatment [35,211]. For example, compounds like colchicine, camptothecin and
podophyllotoxin derivatives have showed limited use due to the side effects. In some
cases, compounds such as SFN or vinca alkaloids present limited effect and they are
used in combination with other agents. In this section, several challenges and strategies
proposed to solve the drawbacks of these compounds will be discussed. Apart from
these challenges, the discovery and development of possible phytochemical compounds
employed clinically also has to face other challenges related to the extraction synthesis,
optimization and characterization of phytochemicals anticancer compounds. Thus, new
advances in analytical technology and computational methodologies, to facilitate the
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identification of new phytochemicals, optimize their extraction and/or opt for its chemical
synthesis or modifications are expected.
4.1. Limited Solubility and Poor Absortion
As mentioned in previous sections, some compounds present low availability, which is
one of the main reasons of the limited potential of phytochemicals. To solve bioavailability
limitations related to stability, absorption and metabolism, lipid-based formulations (such
as microencapsulation, liposomes, nano-emulsion, etc.) and nanotechnology have been
considered as a suitable approach to enhance aqueous solubility, stability, target specific to
cancerous cells and even reduce the quantity of the phytochemical compound to achieve
secure therapeutic levels [211,212]. For example, the administration of the vinca alkaloids
has been further improved by including them into micro- or nano-capsules, such as lipo-
somes or micelles (“Liposome-encapsulated vinca alkaloids and their use in combating
tumors” patent no. US4952408A; “Nano anticancer micelles of vinca alkaloids entrapped in
polyethylene glycolylated phospholipids” patent no. US8765181B2). The encapsulation of
core ingredients permits a controlled release and protects the bioactivity from external fac-
tors that may affect the performance. Among them, liposomes named after Marqibo®, have
been approved by FDA to treat adult leukemia [54]. Similar efforts have been conducted
to improve the solubility of paclitaxel, and several nano-technological platforms have
been developed including polymeric nanoparticles (Abraxane®), polymeric conjugates
(Xyotax), polymeric micelles (Genexol-PM, NK 105) and liposomes (LEP-ETU). However,
although a large number of nano-medicines has been investigated in the last decades,
only few nano-formulations have achieved their use in clinical trials, with even fewer
being approved for clinical application. For example, the hydroxypropyl-methacrylamide
copolymer–PTX developed by the pharmaceutical Pfizer has stopped in Phase I due to the
high neurotoxicity in rats during the study. Poly (L-glutamic acid)-paclitaxel (PG-TXL)
belongs to the few formulations that reached phase III clinical trials. Unfortunately, the
development of PG-TXL stopped in 2016 due to the inability to show significant improve-
ment over current standard care [213]. In the case of irinotecan, some studies have revealed
that its therapeutic use is limited due to its hydrophobicity, low stability at physiologic
pH, and side effects. These issues could be solved by new drug formulations containing
nanoparticles, polymer conjugates, dendrimers, peptides, and carbohydrates [64].
Regarding compounds in clinical studies, as previously mentioned, low solubility and
availability are some of the main limitations that hinder their possible use for cancer treat-
ment. For example, it has been reported that resveratrol has a circulation half-life of several
minutes, while quercetin is generally present at low micromolar concentrations in blood,
insufficient for a potent anticancer activity [214]. Thus, numerous studies have evaluated
innovative strategies to enhance their availability, including nano-formulations, liposomes,
nanoparticles, etc. For example, gingerol formulated in proliposomes showed a higher
inhibition of HepG2 cancer cells in vitro and also a higher oral bioavailability in vivo [147].
In other study, gold-coated iron oxide nanoparticles improved significantly the stability
and activity of SFN against human breast cancer cells [215]. Recently, mesoporous silica
nanoparticles conjugated with hyaluronic acid were employed as a drug delivery system
of curcumin, and the anticancer activity was measured in vitro and in vivo. The results
showed that the delivery system enhanced the anticancer activity in both assays, which
may attributed to a higher bioavailability [216].
Nowadays, several clinical trials have been performed using innovative strategies to
enhance the bioavailability of chemotherapeutic drugs, as recorded in other reviews [212,214].
However, these studies are few compared with the numerous works published evaluating
novel strategies. Therefore, it is expected that more clinical trials will be conducted in
the future.
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4.2. Combination of Phytochemicals with Conventional Chemotherapeutics
Some authors have pointed out that cancer treatment with a single-target chemical
agent is not entirely effective since it is difficult to achieve optimal cytotoxic effects in cancer
cells due to their rapid molecular adaptations. In addition, some phytochemicals currently
in clinical evaluation present limited effects on their own [217]. Therefore, a combinatorial
approach of these compounds with conventional chemotherapeutics may achieve a syn-
ergistic effect that increases toxicity in cancer cells (associated to the sensitization of the
cancer cells to the drugs, attributed to the phytochemicals), reduces therapeutic doses and
also toxicity concerns [214,217,218]. In this sense, numerous studies have evaluated the effi-
ciency of this combination and have been compiled extensively in recent reviews [116,219].
For example, resveratrol has been successfully used as adjuvant of several conventional
chemotherapeutic drugs, such as temozolomide, doxorubicin and paclitaxel on in vitro
assays and mice models [114–116]. Other compound commonly employed as chemosen-
sitizing agent is curcumin. For example, when combining curcumin with docetaxel, a
decrease in drug resistance was observed in breast cancer cells [220]. Similar results were
also observed combined with vincristine, paclitaxel, irinotecan and cisplatin, enhancing the
efficacy of these drugs, compared to single treatment [127,128,221,222]. Recently, gingerol
has been found to enhance the sensitivity of in vitro gastric cancer cells to cisplatin [146],
and the sensitivity of liver cancer cells to doxorubicin [145]. Other compounds that have
been employed in combinatory assays appeared in Table 3, like apigenin, betulinic acid
and berberine. In addition, as could be observed in Table 2, the combination strategy has
been also assessed in clinical trials. Thus, although more studies are still necessary, it seems
that the use of phytochemicals as chemosensitizing may be beneficial in cancer therapy.
5. Conclusions
Traditional plants have been historically considered as an endless source of new com-
pounds for the development of new pharmaceuticals and drugs. Therefore, nowadays
researchers have at their complete disposal, plenty of ethnomedicinal and ethnopharmaco-
logical information of very different plant species which is a tool for selecting candidates
and lead the research to those plants more promising. As a result of this knowledge,
different examples of phytochemicals with medicinal properties against different diseases
can be found throughout the literature.
Cancer is a complex disease that every year costs several millions of human lives.
The uncontrolled proliferation of cells causes the incorrect functioning of the body, with a
long list of symptoms and finally, death. So, given the health and social important of this
disease, but also its economic impact on the health system, new therapeutic alternatives
are being continuously investigated. For this purpose, it is essential to consider some
factors such as clinical trials, efficacy, the induced tumorigenic changes, possible side
effects and toxicity of the pharmaceuticals. In this context, a variety of phytochemicals
obtained from plants have been discovered and are currently used in cancer therapies. In
the present review, some examples such as vinca alkaloids, paclitaxel or irinotecan, that
have demonstrated to exert anticancer effects on clinical trials and have been approved for
clinical use are collected. Nevertheless, these compounds are not exempt of limitations,
such as low solubility, restricted effect on their own, negative side-effects, etc. This article
also highlights some compounds that are being investigated in pre-clinical and clinical
stages, such as SFN and different phenolic compounds, which have shown interesting
results. However, more clinical trials are still necessary before their further safe application.
At last, after a brief discussion of the information collected on the manuscript, an
attempt has been made to identify which are the main challenges of anticancer phytochem-
icals, current needs and future research lines. Low availability is a target challenge for
this area, which is now focused on the development and improvement of drug delivery
systems, such as nano-based formulations. Moreover, many of these compounds have been
demonstrated to be effective chemosensitizing agents, so they could be used combined
with conventional chemotherapeutics. In this sense, more clinical trials evaluating the
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efficacy of the systems to enhance availability and combinatory trials should be performed
before considering a compound for its use alone or in combination with other drugs.
The manuscript brings to light the need for more large-scale clinical trials and standard-
ization procedures to validate phytochemicals in anticancer therapy. Thus, it is essential
the coordinate work of interdisciplinary areas like medicinal chemistry, pharmacology,
biochemistry and biology to deeply understand the availability, efficacy, safety, mechanism
of action and synergistic effects of these new drugs. Therefore, to address all the limitations
and needs of this research area, this review aimed at compiling the information about the
current phytochemicals used for cancer treatment, promising candidates and to identify
those fundamental challenges for the development of new alternatives.
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173. Karatoprak, G.Ş.; Küpeli Akkol, E.; Genç, Y.; Bardakci, H.; Yücel, Ç.; Sobarzo-Sánchez, E. Combretastatins: An Overview of
Structure, Probable Mechanisms of Action and Potential Applications. Molecules 2020, 25, 2560. [CrossRef]
174. Kim, S.H.; Lee, J.M.; Kim, S.C.; Park, C.B.; Lee, P.C. Proposed cytotoxic mechanisms of the saffron carotenoids crocin and crocetin
on cancer cell lines. Biochem. Cell Biol. 2014, 92, 105–111. [CrossRef] [PubMed]
175. Hire, R.R.; Srivastava, S.; Davis, M.B.; Kumar Konreddy, A.; Panda, D. Antiproliferative Activity of Crocin Involves Targeting of
Microtubules in Breast Cancer Cells. Sci. Rep. 2017, 7, 1–11. [CrossRef]
176. Hoshyar, R.; Mollaei, H. A comprehensive review on anticancer mechanisms of the main carotenoid of saffron, crocin.
J. Pharm. Pharmacol. 2017, 69, 1419–1427. [CrossRef] [PubMed]
177. Zhang, Y.; Zhao, Y.; Guo, J.; Cui, H.; Liu, S. Anticancer activity of safranal against colon carcinoma is due to induction of apoptosis
and G2/M cell cycle arrest mediated by suppression of mTOR/PI3K/Akt pathway. J. B.U.ON. 2018, 23, 574–578.
178. Stahlhut, M.; Bertelsen, M.; Høyer-Hansen, M.; Zibert, J.R. Ingenol Mebutate-Induced Cell Death Patterns in Normal and Cancer
Epithelial Cells. J. Drugs Dermatol. 2012, 11, 707–712.
179. Silva, V.A.O.; Rosa, M.N.; Martinho, O.; Tanuri, A.; Lima, J.P.; Pianowski, L.F.; Reis, R.M. Modified ingenol semi-synthetic
derivatives from Euphorbia tirucalli induce cytotoxicity on a large panel of human cancer cell lines. Investig. New Drugs 2019,
37, 1029–1035. [CrossRef]
180. Chen, Z.; Liu, W.; Qin, Z.; Liang, X.; Tian, G. Geniposide exhibits anticancer activity to medulloblastoma cells by downregulating
microRNA-373. J. Biochem. Mol. Toxicol. 2020, 34. [CrossRef]
181. Shanmugam, M.K.; Shen, H.; Tang, F.R.; Arfuso, F.; Rajesh, M.; Wang, L.; Kumar, A.P.; Bian, J.; Goh, B.C.; Bishayee, A.; et al.
Potential role of genipin in cancer therapy. Pharmacol. Res. 2018, 133, 195–200. [CrossRef] [PubMed]
182. Lou, J.S.; Bi, W.C.; Chan, G.K.L.; Jin, Y.; Wong, C.W.; Zhou, Z.Y.; Wang, H.Y.; Yao, P.; Dong, T.T.X.; Tsim, K.W.K. Ginkgetin induces
autophagic cell death through p62/SQSTM1- mediated autolysosome formation and redox setting in nonsmall cell lung cancer.
Oncotarget 2017, 8, 93131–93148. [CrossRef]
183. Jeon, Y.J.; Jung, S.N.; Yun, J.; Lee, C.W.; Choi, J.; Lee, Y.J.; Han, D.C.; Kwon, B.M. Ginkgetin inhibits the growth of DU-145
prostate cancer cells through inhibition of signal transducer and activator of transcription 3 activity. Cancer Sci. 2015, 106, 413–420.
[CrossRef]
184. Park, Y.; Woo, S.H.; Seo, S.K.; Kim, H.; Noh, W.C.; Lee, J.K.; Kwon, B.M.; Min, K.N.; Choe, T.B.; Park, I.C. Ginkgetin induces cell
death in breast cancer cells via downregulation of the estrogen receptor. Oncol. Lett. 2017, 14, 5027–5033. [CrossRef]
185. Li, M.; Li, B.; Xia, Z.M.; Tian, Y.; Zhang, D.; Rui, W.J.; Dong, J.X.; Xiao, F.J. Anticancer effects of five biflavonoids from ginkgo
biloba l. Male flowers in vitro. Molecules 2019, 24, 1496. [CrossRef]
186. Wang, J.; Zhang, Y.S.; Thakur, K.; Hussain, S.S.; Zhang, J.G.; Xiao, G.R.; Wei, Z.J. Licochalcone A from licorice root, an inhibitor
of human hepatoma cell growth via induction of cell apoptosis and cell cycle arrest. Food Chem. Toxicol. 2018, 120, 407–417.
[CrossRef] [PubMed]
187. Yu, S.J.; Cho, I.A.; Kang, K.R.; Jung, Y.R.; Cho, S.S.; Yoon, G.; Oh, J.S.; You, J.S.; Seo, Y.S.; Lee, G.J.; et al. Licochalcone-E induces
caspase-dependent death of human pharyngeal squamous carcinoma cells through the extrinsic and intrinsic apoptotic signaling
pathways. Oncol. Lett. 2017, 13, 3662–3668. [CrossRef]
188. Peng, J.; Fan, G.; Wu, Y. Preparative isolation of four new and two known flavonoids from the leaf of Patrinia villosa Juss. by
counter-current chromatography and evaluation of their anticancer activities in vitro. J. Chromatogr. A 2006, 1115, 103–111.
[CrossRef] [PubMed]
189. Choudhury, D.; Ganguli, A.; Dastidar, D.G.; Acharya, B.R.; Das, A.; Chakrabarti, G. Apigenin shows synergistic anticancer
activity with curcumin by binding at different sites of tubulin. Biochimie 2013, 95, 1297–1309. [CrossRef]
190. Al-Dabbagh, B.; Elhaty, I.A.; Elhaw, M.; Murali, C.; Al Mansoori, A.; Awad, B.; Amin, A. Antioxidant and anticancer activities of
chamomile (Matricaria recutita L.). BMC Res. Notes 2019, 12, 3. [CrossRef] [PubMed]
191. Srivastava, J.K.; Gupta, S. Antiproliferative and apoptotic effects of chamomile extract in various human cancer cells. J. Agric.
Food Chem. 2007, 55, 9470–9478. [CrossRef]
192. Li, X.L.; Wang, C.Z.; Mehendale, S.R.; Sun, S.; Wang, Q.; Yuan, C.S. Panaxadiol, a purified ginseng component, enhances the
anti-cancer effects of 5-fluorouracil in human colorectal cancer cells. Cancer Chemother. Pharmacol. 2009, 64, 1097–1104. [CrossRef]
Pharmaceuticals 2021, 14, 157 27 of 28
193. Sun, M.; Ye, Y.; Xiao, L.; Duan, X.; Zhang, Y.; Zhang, H. Anticancer effects of ginsenoside Rg3 (Review). Int. J. Mol. Med. 2017,
39, 507–518. [CrossRef] [PubMed]
194. Tripathi, M.; Reddy, P.; Rawat, D. Noscapine and its analogues as anti- cancer agents. Chem. Biol. Interface 2014, 4, 1–22.
195. Falodun, A.; Engel, N.; Kragl, U.; Nebe, B.; Langer, P. Novel anticancer alkene lactone from Persea americana. Pharm. Biol. 2013,
51, 700–706. [CrossRef] [PubMed]
196. Hu, C.X.; Zuo, Z.L.; Xiong, B.; Ma, J.G.; Geng, M.Y.; Lin, L.P.; Jiang, H.L.; Ding, J. Salvicine functions as novel topoisomerase II
poison by binding to ATP pocket. Mol. Pharmacol. 2006, 70, 1593–1601. [CrossRef] [PubMed]
197. Meng, L.H.; Ding, J. Salvicine, a novel topoisomerase II inhibitor, exerts its potent anticancer activity by ROS generation.
Acta Pharmacol. Sin. 2007, 28, 1460–1465. [CrossRef]
198. Deng, F.; Lu, J.J.; Liu, H.Y.; Lin, L.P.; Ding, J.; Zhang, J.S. Synthesis and antitumor activity of novel salvicine analogues.
Chinese Chem. Lett. 2011, 22, 25–28. [CrossRef]
199. Wu, C.F.; Klauck, S.M.; Efferth, T. Anticancer activity of cryptotanshinone on acute lymphoblastic leukemia cells. Arch. Toxicol.
2016, 90, 2275–2286. [CrossRef]
200. Chen, L.; Wang, H.J.; Xie, W.; Yao, Y.; Zhang, Y.S.; Wang, H. Cryptotanshinone inhibits lung tumorigenesis and induces apoptosis
in cancer cells in vitro and in vivo. Mol. Med. Rep. 2014, 9, 2447–2452. [CrossRef] [PubMed]
201. Li, S.; Wang, H.; Hong, L.; Liu, W.; Huang, F.; Wang, J.; Wang, P.; Zhang, X.; Zhou, J. Cryptotanshinone inhibits breast cancer cell
growth by suppressing estrogen receptor signaling. Cancer Biol. Ther. 2015, 16, 176–184. [CrossRef]
202. Qin, T.; Rasul, A.; Sarfraz, A.; Sarfraz, I.; Hussain, G.; Anwar, H.; Riaz, A.; Liu, S.; Wei, W.; Li, J.; et al. Salvianolic acid A &
B: Potential cytotoxic polyphenols in battle against cancer via targeting multiple signaling pathways. Int. J. Biol. Sci. 2019,
15, 2256–2264.
203. Deep, G.; Oberlies, N.H.; Kroll, D.J.; Agarwal, R. Isosilybin B and isosilybin A inhibit growth, induce G1 arrest and cause
apoptosis in human prostate cancer LNCaP and 22Rv1 cells. Carcinogenesis 2007, 28, 1533–1542. [CrossRef] [PubMed]
204. Dhanalakshmi, S.; Agarwal, C.; Singh, R.P.; Agarwal, R. Silibinin up-regulates DNA-protein kinase-dependent p53 activation to
enhance UVB-induced apoptosis in mouse epithelial JB6 cells. J. Biol. Chem. 2005, 280, 20375–20383. [CrossRef]
205. Scambia, G.; De Vincenzo, R.; Ranelletti, F.O.; Panici, P.B.; Ferrandina, G.; D’Agostino, G.; Fattorossi, A.; Bombardelli, E.; Mancuso,
S. Antiproliferative effect of silybin on gynaecological malignancies: Synergism with cisplatin and doxorubicin. Eur. J. Cancer
1996, 32, 877–882. [CrossRef]
206. Ramasamy, K.; Agarwal, R. Multitargeted therapy of cancer by silymarin. Cancer Lett. 2008, 269, 352–362. [CrossRef] [PubMed]
207. Zi, X.; Feyes, D.K.; Agarwal, R. Anticarcinogenic effect of a flavonoid antioxidant, silymarin, in human breast cancer cells
MDA-MB 468: Induction of G1 arrest through an increase in Cip1/p21 concomitant with a decrease in kinase activity of
cyclin-dependent kinases and associated cyclins. Clin. Cancer Res. 1998, 4, 1055–1064.
208. Shukla, Y.; Singh, M. Cancer preventive properties of ginger: A brief review. Food Chem. Toxicol. 2007, 45, 683–690. [CrossRef]
209. Al-Abbasi, F.A.; Alghamdi, E.A.; Baghdadi, M.A.; Alamoudi, A.J.; El-Halawany, A.M.; El-Bassossy, H.M.; Aseeri, A.H.; Al-Abd,
A.M. Gingerol synergizes the cytotoxic effects of doxorubicin against liver cancer cells and protects from its vascular toxicity.
Molecules 2016, 21, 886. [CrossRef]
210. Zhu, Y.; Warin, R.F.; Soroka, D.N.; Chen, H.; Sang, S. Metabolites of Ginger Component [6]-Shogaol Remain Bioactive in Cancer
Cells and Have Low Toxicity in Normal Cells: Chemical Synthesis and Biological Evaluation. PLoS ONE 2013, 8, 54677. [CrossRef]
[PubMed]
211. Jafri, A.; Amjad, S.; Bano, S.; Kumar, S.; Serajuddin, M.; Arshad, M. Efficacy of Nano-phytochemicals Over Pure Phytochemicals
Against Various Cancers: Current Trends and Future Prospects. In Nanomaterials and Environmental Biotechnology; Bhushan, I.,
Singh, V.K., Tripathi, D.K., Eds.; Springer: New York, NY, USA, 2020; pp. 407–424.
212. Singh, V.K.; Arora, D.; Ansari, M.I.; Sharma, P.K. Phytochemicals based chemopreventive and chemotherapeutic strategies and
modern technologies to overcome limitations for better clinical applications. Phyther. Res. 2019, 33, 3064–3089. [CrossRef]
213. Zhao, J.; Koay, E.J.; Li, T.; Wen, X.; Li, C. A hindsight reflection on the clinical studies of poly(l-glutamic acid)-paclitaxel.
Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2018, 10, 1–18. [CrossRef]
214. Lagoa, R.; Silva, J.; Rui, J.; Bishayee, A. Advances in phytochemical delivery systems for improved anticancer activity. Biotech-
nol. Adv. 2020, 38, 107382. [CrossRef] [PubMed]
215. Manjili, H.K.; Ma, L.; Tavaddod, S.; Mashhadikhan, M. D, L-Sulforaphane Loaded Fe3O4@ Gold Core Shell Nanoparticles: A
Potential Sulforaphane Delivery System. PLoS ONE 2016, 11, e0151344. [CrossRef]
216. Ghosh, S.; Dutta, S.; Sarkar, A.; Kundu, M.; Sil, P.C. Targeted delivery of curcumin in breast cancer cells via hyaluronic acid
modified mesoporous silica nanoparticle to enhance anticancer efficiency. Colloids Surf. B Biointerfaces 2021, 197, 111404. [CrossRef]
217. Zhou, X.; Seto, S.W.; Chang, D.; Kiat, H.; Razmovski-Naumovski, V.; Chan, K.; Bensoussan, A. Synergistic effects of Chinese
herbal medicine: A comprehensive review of methodology and current research. Front. Pharmacol. 2016, 7, 1–16. [CrossRef]
218. Singh, S.; Sharma, B.; Kanwar, S.S.; Kumar, A. Lead phytochemicals for anticancer drug development. Front. Plant Sci. 2016,
7, 1–13. [CrossRef]
219. Zhang, M.; Chen, X.; Radacsi, N. New tricks of old drugs: Repurposing non-chemo drugs and dietary phytochemicals as
adjuvants in anti-tumor therapies. J. Control. Release 2021, 329, 96–120. [CrossRef]
220. Aung, T.N.; Qu, Z.; Kortschak, R.D.; Adelson, D.L. Understanding the effectiveness of natural compound mixtures in cancer
through their molecular mode of action. Int. J. Mol. Sci. 2017, 18, 656. [CrossRef] [PubMed]
Pharmaceuticals 2021, 14, 157 28 of 28
221. Tang, X.Q.; Bi, H.; Feng, J.Q.; Cao, J.G. Effect of curcumin on multidrug resistance in resistant human gastric carcinoma cell line
SGC7901/VCR. Acta Pharmacol. Sin. 2005, 26, 1009–1016. [CrossRef]
222. Ganta, S.; Amiji, M. Coadministration of paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance
in tumor cells. Mol. Pharm. 2009, 6, 928–939. [CrossRef]
